tbuckley/cabot-search huggingface dataset:
Generation of Specific Human CD8+ T Cell Responses to the Myeloproliferative Disorder Associated V617F Mutated JAK2 Kinase by Use of Analog Peptide Vaccine Candidates.
Authors: Rena J. May, Tanya Korontsvit, Victoriya Zakhaleva, Marta Gomez, Tao Dao, David A. Scheinberg
Journal: Blood (2005)
Patterns of maintenance treatment (Tx) following first-line bevacizumab (bev) plus chemotherapy (CT) for metastatic colorectal cancer (mCRC): Results from a large German community-based cohort study.
Authors: D. Arnold, V. Petersen, M. Kindler, M. Schulze, J. Seraphin, A. Hinke, S. Srock, A. Kutscheidt
Journal: Journal of Clinical Oncology (2011)

502 Background: As a result of the long PFS with bev-containing combinations in first-line mCRC, discontinuation of at least one CT component after an “induction” period and continuation with “maintenance” Tx is common. It is anticipated that duration and patterns of maintenance Tx may affect PFS. Methods: We analysed induction and maintenance Tx in a large observational cohort study of bev + various first-line CT regimens. Results of the entire cohort were reported earlier [Arnold et al. ASCO GI 2010]. Results: From Jan 05 to Jun 08, 1620 patients (pts) were enrolled at 261 sites. 1,307 pts (81% of total) received bev + fluoropyrimidine-oxaliplatin (n=306, 23.5%) or fluoropyrimidine-irinotecan (n=1,001, 76.5%). While Tx reduction was not predefined, after induction 271 pts (21%) received de-escalated maintenance Tx: bev alone (n=106; 8%), or bev + CT (n=165; 13%). Median Tx duration for pts receiving bev alone was 8.7 mo for induction and 3.2 mo for maintenance. Pts receiving bev + CT maintenance had shorter induction (5.1 mo) but longer maintenance (4.4 mo). Median PFS (after induction) with bev maintenance was 10.8 mo vs. 13.5 mo for bev + CT maintenance. Data are available from 161 pts with bev + CT maintenance after induction with oxaliplatin (n=97) or irinotecan (n=64). Median total Tx duration was 9.6 mo for oxaliplatin-based induction and 10.9 mo for irinotecan-based induction; median induction duration was 4.1 and 5.5 mo, and maintenance duration was 4.3 and 4.4 mo, respectively. Median PFS (after induction) was 12.8 and 14.1 mo, respectively. Progressive disease (PD) has not yet occurred in 165 pts (62% of maintenance cohort). A high proportion of pts received Tx until PD (74% and 79%, respectively). Conclusions: Both de-escalation strategies led to long PFS and a high number of pts treated ′until PD′. A trend towards better PFS was observed in pts receiving bev + CT maintenance vs. single-agent bev. The ongoing randomized AIO KRK 0207 trial is prospectively evaluating three different maintenance strategies after induction with bev + fluoropyrimidine + oxaliplatin. [Table: see text]
Single Dose Pharmacokinetics of a Recombinant FVIIa In Factor VIII KO Mice, Rats, and Cynomolgus Monkeys
Authors: Gerald Hoebarth, Susan Kubik, Martin Wolfsegger, John-Philip Lawo, Alfred Weber, Herbert Gritsch, Hartmut J. Ehrlich, Friedrich Scheiflinger, Hans Peter Schwarz, Eva-Maria Muchitsch
Journal: Blood (2010)
Mutations in DONSON disrupt replication fork stability and cause microcephalic dwarfism
Authors: John J Reynolds, Louise S Bicknell, Paula Carroll, Martin R Higgs, Ranad Shaheen, Jennie E Murray, Dimitrios K Papadopoulos, Andrea Leitch, Olga Murina, Žygimantė Tarnauskaitė, Sarah R Wessel, Anastasia Zlatanou, Audrey Vernet, Alex von Kriegsheim, Rachel M A Mottram, Clare V Logan, Hannah Bye, Yun Li, Alexander Brean, Sateesh Maddirevula, Rachel C Challis, Kassiani Skouloudaki, Agaadir Almoisheer, Hessa S Alsaif, Ariella Amar, Natalie J Prescott, Michael B Bober, Angela Duker, Eissa Faqeih, Mohammed Zain Seidahmed, Saeed Al Tala, Abdulrahman Alswaid, Saleem Ahmed, Jumana Yousuf Al-Aama, Janine Altmüller, Mohammed Al Balwi, Angela F Brady, Luciana Chessa, Helen Cox, Rita Fischetto, Raoul Heller, Bertram D Henderson, Emma Hobson, Peter Nürnberg, E Ferda Percin, Angela Peron, Luigina Spaccini, Alan J Quigley, Seema Thakur, Carol A Wise, Grace Yoon, Maha Alnemer, Pavel Tomancak, Gökhan Yigit, A Malcolm R Taylor, Martin A M Reijns, Michael A Simpson, David Cortez, Fowzan S Alkuraya, Christopher G Mathew, Andrew P Jackson, Grant S Stewart
Journal: Nature Genetics (2017)
Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)
Authors: L. Toppo, G. Tomasello, M. Ghidini, W. Liguigli, S. Lazzarelli, C. Caminiti, G. Maglietta, R. Passalacqua
Journal: Annals of Oncology (2016)
T Cell Pathway Deficiencies in Chronic Lymphocityc Leukemia: Partial Restoration with OKT3/IL-2 Activation.
Authors: Mauro Di Ianni, Lorenzo Moretti, Beatrice Del Papa, Maria De Ioanni, Adelmo Terenzi, Moira Bazzucchi, Raffaella Ciurnelli, Franca Falzetti, Antonio Tabilio
Journal: Blood (2007)
Ultra-rapid, sensitive, and fully automated extended RAS testing for metastatic colorectal cancer – evaluation of an NRAS/BRAF/EGFR492 module
Authors: E. Vercauteren, E. Bellon, K. Vermeiren, F. De Freitas, E. De Haes, S. Van Gestel, S. Murray, M. Grauslund, L. Melchior, N. D'Haene, M. Le Mercier, B. Bellosillo, C. Montagut, M. Van Brussel, E. Sablon, G. Maertens
Journal: Annals of Oncology (2016)
Risk Factors for Outcome after Haploidentical Hematopoietic Stem Cell Transplant in Children with Very High Risk Acute Lymphoblastic Leukemia: Impact of Centre Experience. A Survey on Behalf of the ALWP and PDWP of the EBMT.
Authors: Thomas Klingebiel, Jacqueline Cornish, Myriam Labopin, Franco Locatelli, Adriana Balduzzi, Joanne Owoc, Franca Fagioli, Dan Engelhard, Christina Peters, Giorgio Dini, Vanderson Rocha
Journal: Blood (2006)
Sirolimus, Tacrolimus and Low-Dose Methotrexate Based Graft-Versus-Host Disease (GVHD) Prophylaxis After Non-Ablative or Reduced Intensity Conditioning in Related and Unrelated Donor Allogeneic Stem Cell Transplantation: Decreased Severe Early aGVHD but Persistence of Late Acute Gvhd
Authors: Ceberio Izaskun, Sean Devlin, Craig S. Sauter, Juliet N Barker, Hugo Castro-Malaspina, Sergio A Giralt, Doris M Ponce, Lauren Lechner, Anne Marie R Gonzales, Jenna D Goldberg, Miguel-Angel Perales
Journal: Blood (2012)
DRES-10. THE ADVERSE IMPACT OF TEMOZOLOMIDE THERAPY AT INITIAL DIAGNOSIS OF GRADE II GLIOMA ON OVERALL SURVIVAL
Authors: Ben Zhang, Paul Decker
Journal: Neuro-Oncology (2016)

Recent data suggests that temozolomide (TMZ)-treated grade II gliomas are often hypermutated at recurrence. We tested our hypothesis that early TMZ therapy is detrimental in patients with grade II gliomas, because of chemotherapy resistance at tumor recurrence. We identified 120 patients treated at our institution between 1995 and 2016 who were initially diagnosed with grade II glioma, and subsequently developed recurrent tumors of any grade. Overall survival after diagnosis (OS) was estimated using the Kaplan-Meier method. The associations of TMZ treatment status with survival were evaluated using Cox proportional hazards regression models. Progression free survival (PFS) between (i) initial diagnosis and first recurrence and (ii) after systemic therapy at first recurrence were also evaluated. The median OS for patients treated with or without TMZ at diagnosis were 81 and 130 months, respectively (HR 1.75, 95% CI 1.07-2.81, p=0.027). This association remained significant after multivariate adjustments for covariates including histology, IDH mutation, 1p/19q codeletion, age, extent of resection and radiation therapy. The duration between initial diagnosis and first recurrence was similar between the TMZ treatment and no treatment arms. The median PFS after systemic therapy at first recurrence were 4 months and 36 months, respectively, for patients who had or had not received TMZ at initial diagnosis (HR 4.69, 95% CI 2.85-7.70, p<0.0001). Early TMZ therapy may reduce overall survival in patients with grade II glioma because of substantial chemotherapy resistance at recurrence.
Characterization of a Megakaryocyte-Specific Enhancer of the Key Hemopoietic Transcription Factor GATA1.
Authors: Boris Guyot, Kasumi Murai, Yuko Fujiwara, Veronica Valverde-Garduno, Michele Hammett, Sara Wells, Neil Dear, Stuart H. Orkin, Catherine Porcher, Paresh Vyas
Journal: Blood (2005)
Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma
Authors: Stéphanie Guidez, Guillemette Fouquet, Hélène Demarquette, Morgane Nudel, Eileen Boyle, Marie Lorraine Chretien, Denis Caillot, Lionel Karlin, Cyrille Hulin, Olivier Decaux, Bertrand Arnulf, Cécile Fohrer, Margaret MACRO, Charles Lancesseur, Murielle Roussel, Benjamin Hebraud, Thierry Facon, Xavier Leleu
Journal: Blood (2015)
In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Imatinib (IM) and Chemotherapy in Combination Improve Remission Rate, Stem Cell Transplantation Rate and Long-Term Outcome
Authors: Tamara Intermesoli, Chiara Cattaneo, Enrico Maria Pogliani, Eros Di Bona, Claudio Romani, Vincenzo Cassibba, Agostino Cortelezzi, Francesco Mannelli, Fabio Ciceri, Daniele Mattei, Orietta Spinelli, Manuela Tosi, Elena Oldani, Alessandro Rambaldi, Renato Bassan
Journal: Blood (2012)
A new device to monitor the intraoperative lower oesophagealsphincter pressure during the laparoscopic antirefluxsurgery-the feasibility study
Authors: Petr Kysela, Zdeněk Kala, Vladimír Procházka, Filip Marek, Jiří Dolina, Radek Kroupa
Journal: Endoscopy (2009)

Number of manipulations with the probe and number of probe
displacements was significantly lower in the newly designed
calibrations probe thus giving probably more reliable values
according to which the surgeon forms the wrap.The desired
influence of the new device on the postoperative dysphagia
occure has to be fevalued yet.AC
Preliminary efficacy and safety data of nivolumab in never smoker patients with advanced squamous NSCLC: Experience from Italian sites participating in the Expanded Access Programme (EAP)
Authors: M. Vitali, L. Crinò, A.F. Logroscino, A. Ardizzoni, S. Caponnetto, L. Landi, P. Bordi, C. Luana, F. Barbieri, A. Santo, M. Santarpia, G. Carteni, E. Mini, E. Vasile, F. Morgillo, F. De Galitiis, R. Conca, M. Macerelli, N. Tedde, F. Vitiello
Journal: Annals of Oncology (2016)
Basic and Clinical Immunology.
Journal: Annals of Internal Medicine (1979)

This text and review has been updated and revised since the last edition in 1974. The normal immunologic function and disease processes are presented clearly. New features include emphasis on normal immunologic function and disease processes; a new immunotherapy section describing drugs and other therapies; an updated immunologic laboratory tests section featuring new methods and techniques; a chapter on molecular genetic techniques for clinical analysis of the immune system; and numerous illustrations. This work is intended for students, physicians and biotechnology professionals.
IMST-23. TUMOR IMMUNOSUPPRESSION IS TIGHTLY COUPLED WITH IDH WILD-TYPE IN GLIOMA PATIENTS
Authors: Luyan Mu, Changlin Yang, Yunhe Gu, Haitao Ge, Yifan (Emily) Chang, Gabriel De Leon, Elias Sayour, Songsong Xia, Hongbo Bao, Long Yu, Linchun Jin, Jiping Qi, Jiahang Sun, Xiang Gao, Ying Ching Song, Paul Kubilis, Duane Mitchell, Zhiguo Lin, Jianping Huang
Journal: Neuro-Oncology (2016)

Malignant gliomas are heterogeneous brain tumors with capacity for aggressive disease progression influenced by suppressive immunoediting. Identifying key factors involved in glioma immunosuppression is critical for the development of effective immunotherapy for chemo/radiation resistant gliomas. We hypothesize that the genetic landscape created by IDH-mutant gliomas predominantly controls tumor immune infrastructure. Paired surgical resected tumors from 35 LGGs and 15 GBMs were evaluated pre- and post-progression; genetic analysis of primary tumors culled from TCGA datasets was performed to determine the link between IDH-mutant status and immune-suppression. We found that there were distinct immune landscapes between IDH-mutant versus IDH-wild-type gliomas. IDH-wild-type tumors displayed higher tumor infiltrating inhibitory immune cell populations (i.e. T regulatory cells and tumor-associated macrophages). The genetic analysis of large cohort of patients demonstrated that the IDH wild-type is coupled with elevated gene expressions associated immunosuppression than mutant tumors. Elevated gene expression levels of the programmed death-1 ­receptor (PD-1) ligands CD274 and PDCD1LG2 were mainly detected in IDH-wild-type tumors that were linked with tumor associated their promoter hypo-methylation. These results suggest that IDH mutations associate with glioma immunosuppressive networks by attracting inhibitory cell populations and manipulating checkpoint ligand expression. Immunotherapeutic strategies exploiting the tumor immune-landscape may be a beneficial alternative for chemotherapy/ radiation therapy insensitive IDH-wild-type gliomas.
Endoscopic removal of a proximally migrated biliary metallic stent
Authors: Chuncheng Wu, Juliana Yang, Mei Xu, Wei Liu, Bing Hu
Journal: Endoscopy (2017)

A 37-year-old Asian man had undergone laparoscopic cholecystectomy that was complicated by proximal common bile duct (CBD) stenosis requiring endoscopic retrograde cholangiopancreatography (ERCP) placement of a fully covered self-expandable metal biliary stent (FCSEMS) at a local hospital 8 months previously. His jaundice subsided after the initial stent placement. However, over the next 3 months, he developed recurrent abdominal pain and fever. Repeat imaging showed the stent has migrated proximally.
HuMax CD20 Fully Human Monoclonal Antibody in Chronic Lymphocytic Leuchemia. Early Results from an Ongoing Phase I/II Clinical Trial.
Authors: Bertrand Coiffier, H. Tilly, L. M. Pedersen, T. Plesner, H. Frederiksen, M.H.J. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, J. J. Walewski, M.F. Flensburg, J. Petersen, T. Robak
Journal: Blood (2005)
Quality of life (QoL) and neurotoxicity in germ-cell cancer survivors (GCCS)
Authors: J. Lauritsen, M. Bandak, M.S. Mortensen, M.G.G. Kier, M. Agerbaek, N.V. Holm, R. Gupta, C. Johansen, G. Daugaard
Journal: Annals of Oncology (2016)
The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals
Authors: Sarah E.M. Herman, Amber L. Gordon, Emilia Mahoney, Samantha M. Jaglowski, Kristie A. Blum, Joseph Buggy, Ahmed Hamdy, John C. Byrd, Amy J. Johnson
Journal: Blood (2010)
ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study
Authors: S.-C. Tang, P. Kumthekar, A.J. Brenner, S. Kesari, D. Piccioni, C.K. Anders, J.A. Carillo, P. Chalasani, P. Kabos, S.L. Puhalla, A. Garcia, K. Tkaczuk, M.S. Ahluwalia, N. Lakhani, N. Ibrahim
Journal: Annals of Oncology (2016)
Transforming growth factor beta receptor (TGF&amp;bgr;R) pathway is involved in ligand independent transactivation of AXL receptor in colorectal cancer (CRC) cell lines
Authors: E. Franzese, G. Martini, C. Cardone, T. Troiani, V. Sforza, M.L. Ferrara, V. Belli, P.P. Vitiello, S. Napolitano, N. Zanaletti, P. Vitale, F. De Vita, M. Orditura, F. Morgillo, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2016)
Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
Authors: C. Weekes, J. Berlin, H.-J. Lenz, B. O'Neil, W. Messersmith, S. Cohen, C. Dendinger, S. Shahda, A. Kapoun, C. Zhang, R. Jenner, F. Cattaruzza, L. Xu, J. Dupont, R. Brachmann, S. Uttamsingh, A. Farooki, E. Dotan
Journal: Annals of Oncology (2016)
A Study of the Binding Mode and the In Vitro Activity of the Protein Tyrosine Kinase Inhibitor SKI-606 in the BCR-ABL Positive Cells.
Authors: Tiziana Grafone, Simona Soverini, Gianluca Tasco, Manuela Mancini, Frank Boschelli, Jennifer Golas, David Frauling, Sabrina Colarossi, Emanuela Ottaviani, Alessandra Gnani, Giannoulia Panagiota, Fausto Castagnetti, Rita Casadio, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani
Journal: Blood (2006)
Carfilzomib (CFZ): A Novel Proteasome Inhibitor That Induces Cell Cycle Arrest and Cell Death In Rituximab-Chemotherapy Resistant Lymphoma and Potentiates the Anti-Tumor Activity of Chemotherapeutic Agents
Authors: Juan Gu, Francisco J. Hernandez-Ilizaliturri, Gregory P. Kaufman, Cory Mavis, Myron S. Czuczman
Journal: Blood (2010)
Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies?
Authors: M. Matias, S. Aspeslagh, V. Palomar, E. Lanoy, L. Dercle, C. Even, C. Ferte, A. Hollebecque, A. Marabelle, C. Massard, J.-C. Soria, S. Postel-Vinay
Journal: Annals of Oncology (2016)
New approach to gastric cancer classification based on TP53 mutation
Authors: R. Makuuchi, K. Hatakeyama, M. Terashima, M. Kusuhara, M. Tokunaga, Y. Tanizawa, E. Bando, T. Kawamura, M. Hikage, S. Kaji, K. Ohshima, K. Urakami, K. Yamaguchi
Journal: Annals of Oncology (2016)
ACTR-30. EORTC 1608: A PHASE 1B STUDY OF TG02, AN ORAL CYCLIN-DEPENDENT KINASE 9/5 INHIBITOR, IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA STRATIFIED BY MGMT PROMOTER METHYLATION STATUS
Authors: Emilie Le Rhun, Tracy Parrott, Tom Estok, Thierry Gorlia, Vassilis Golfinopoulos, Michael Weller
Journal: Neuro-Oncology (2016)

TG02 is an orally bioavailable, multi-kinase inhibitor which appears to exert anti-tumor activity mainly by inhibiting cyclin-dependent kinase (CDK) 9, resulting in the depletion of oncoproteins such as induced myeloid leukemia cell differentiation protein (MCL) 1 and MYC (Myelocytomatosis-associated). TG02 exhibits strong activity in glioma models including stem cell models at concentrations likely to be achieved in human patients in vivo and shows promising blood brain barrier penetration. Based on the strong preclinical data for TG02, the EORTC Brain Tumor Group has initiated EORTC 1608 study, a phase 1b dose-escalation and safety study of TG02 in combination with either hypofractionated radiotherapy (cohort A) or temozolomide (cohort B) in elderly patients with newly diagnosed glioblastoma not considered eligible for combined modality treatment. Patient allocation to treatment will be determined by O6-methylguaine DNA methyltransferase (MGMT) promoter methylation status according to European Association of Neuro-Oncology (EANO) guidelines for elderly patients with glioblastoma: unmethylated (cohort A) versus methylated (cohort B). Further, we will explore single agent activity of TG02 in glioblastoma patients aged 18 or more at first progression after temozolomide chemoradiotherapy with progression-free survival at 6 months as the main efficacy endpoint (cohort C). We will report on the current preclinical stage of development of TG02 and update on the clinical trial conducted by the EORTC Brain Tumor Group. TG02 targets a novel oncogenic pathway activated in glioblastoma, warranting studies on its activity in early clinical trials.
CBIO-10. REVERSIBILITY OF GLIOMA STEM CELLS’ SPHERE FORMATION EXPLAINS THEIR IN VITRO BEHAVIOR AND IN VIVO TUMORIGENESIS POTENTIAL
Authors: Thomas Wilson, Dan Zamler, Robert Doherty, Tom Mikkelsen, Ana deCarvalho, Maria Castro, Pedro Lowenstein
Journal: Neuro-Oncology (2016)

It has been shown that glioma cells can grow in two distinct phenotypic forms, as an adherent monolayer and as free floating “tumorspheres”, using highly selected media supplements specific to each condition. It remains unknown, however, whether theses phenotypes are irreversible once they are attained. Our results show that these two states are reversible across several patient derived glioblastoma primary cell cultures (HF2303, IN859, MGG8, IN2045). We further demonstrate that, while reversible, the two phenotypic states have distinct characteristics, important to physiological function and treatment. When measuring proliferation, invasion, migration, chemotaxis and chemosensitivity the two populations had different behavior which could translate to clinical implications. Our findings have implications for our understanding of the cancer stem cell hypothesis and the tumorigenic potential of patient derived glioma cell cultures. Furthermore our results clarify how cell culture conditions can impact experimental results and reproducibility. We then sought to uncover a novel therapeutic approach using genetic profiling across these same four patient derived glioblastoma cell cultures to target the quiescent sphere population. Our screen showed that PRKG1 is upregulated across all four sphere patient derived glioblastoma cell cultures and has been shown to induce apoptosis when activated. In-vitrothe stimulation of PRKG1 activity effectively reduced cell viability in the sphere phenotype. Furthermore our results show that targeting these glioblastoma populations with a chemotherapeutic compound, doxorubicin, in conjunction with the sphere selective target, i.e. PRKG1 agonist, 8-BR-PET-cGMP, elicits additive killing compared to either drug alone. While traditional chemotherapeutics such as doxorubicin or paclitaxel work well on rapidly dividing adherent cells, it has been challenging to target the glioblastoma sphere phenotype. Our data provides support to develop PRKG1 activating drugs to be used as an adjuvant therapy in glioblastoma. This work was supported by NIH-NINDS, the Department of Neurosurgery, and Leah’s Happy Heart Foundation
Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs)
Authors: J. Carles, I. Davis, J.S. de Bono, K. Fizazi, W. Gerritsen, D.E. Rathkopf, C.J. Ryan, F. Saad, T. Steuber, G. Wilding, Y.C. Park, R. Charnas, P. De Porre, H. Van Poppel
Journal: Annals of Oncology (2016)
FDG Brain PET/CT Revealing Bilateral Thalamostriatal Activation During a Symptomatic Episode in a Patient With Kleine-Levin Syndrome
Authors: Clément Drouet, Olivier Morel, Antoine Verger, Eric Guedj, Hatem Boulahdour
Journal: Clinical Nuclear Medicine (2017)

We report the case of a 14-year-old girl with clinically diagnosed Kleine-Levin syndrome. Electroencephalogram and brain MRI were unremarkable. An FDG PET/CT scan was acquired during a symptomatic episode, while she was asleep, and another PET scan was obtained when she was asymptomatic, awake, and quiet. Comparison of both examinations demonstrated a bilateral activation of thalami, caudate nuclei, and lenticular nuclei. These findings may be linked to the implication of thalamostriatal structures in the regulation of sleep and wakefulness.
Heme Oxygenase 1-Induced Resistance to Imatinib In Chronic Myelogenous Leukemia Cells
Authors: Daniele Tibullo, Ignazio Barbagallo, Antonio Branca, Cesarina Giallongo, Piera La Cava, Giovanni Li Volti, Giuseppe A Palumbo, Roberto Motterlini, Angelo Vanella, Francesco Di Raimondo
Journal: Blood (2011)
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
Authors: Diego Cadavid, Laura Balcer, Steven Galetta, Orhan Aktas, Tjalf Ziemssen, Ludo Vanopdenbosch, Jette Frederiksen, Mark Skeen, Glenn J Jaffe, Helmut Butzkueven, Focke Ziemssen, Luca Massacesi, Yi Chai, Lei Xu, Stefanie Freeman
Journal: The Lancet Neurology (2017)
Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study
Authors: G.A. Fisher, E. Wolin, P.L. Kunz, N. Liyanage, B. Mirakhur, S. Pitman Lowenthal, R.F. Pommier, M. Shaheen, A. Vinik
Journal: Annals of Oncology (2016)
Genome-Wide DNA Methylation Analysis Identifies Aberrant Epigenetic Changes in CD8+ T Cells from Chronic Lymphocytic Leukemia Patients
Authors: Jiazhu Wu, Xiaojing Xu, Lirong Pei, Eun-Joon Lee, Austin Shull, Farrukh Awan, Xiaoling Wang, Lei Fan, Li Jianyong, Xu Wei, Huidong Shi
Journal: Blood (2014)